JOINTOWN PHARMACEUTICAL GROUP CO., LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.17 CNY | -2.16% |
|
-0.49% | +16.55% |
| Apr. 29 | Jointown Pharma's Q1 Profit, Revenue Fall 4% | MT |
| Apr. 29 | Jointown Pharmaceutical Group's 2023 Profit Jumps 4% | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 26,006 | 33,241 | 26,919 | 24,052 | 26,691 | 31,107 | - | - |
| Enterprise Value (EV) 1 | 28,388 | 36,125 | 29,021 | 21,882 | 24,319 | 40,352 | 43,667 | 31,107 |
| P/E ratio | 15.4 x | 11.7 x | 11.6 x | 12.2 x | 12.7 x | 14.1 x | 10.5 x | 11.3 x |
| Yield | - | 2.75% | 2.04% | 3.83% | 3.57% | 3.06% | 4.27% | - |
| Capitalization / Revenue | 0.26 x | 0.3 x | 0.22 x | 0.17 x | 0.18 x | 0.18 x | 0.16 x | 0.14 x |
| EV / Revenue | 0.29 x | 0.33 x | 0.24 x | 0.16 x | 0.16 x | 0.24 x | 0.23 x | 0.14 x |
| EV / EBITDA | 10 x | 7.36 x | 6.93 x | 6.21 x | 6.5 x | 7.4 x | 7.1 x | - |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Price to Book | 1.42 x | 1.75 x | 1.31 x | 1.09 x | 1.14 x | 1.38 x | 1.15 x | 1.31 x |
| Nbr of stocks (in thousands) | 3,833,850 | 3,818,311 | 3,814,733 | 3,847,610 | 3,807,514 | 3,807,514 | - | - |
| Reference price 2 | 6.783 | 8.706 | 7.057 | 6.251 | 7.010 | 8.170 | 8.170 | 8.170 |
| Announcement Date | 4/28/20 | 4/26/21 | 4/25/22 | 4/24/23 | 4/26/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 99,497 | 110,860 | 122,407 | 140,424 | 150,140 | 170,336 | 190,955 | 225,315 |
| EBITDA 1 | 2,838 | 4,909 | 4,187 | 3,526 | 3,741 | 5,456 | 6,151 | - |
| EBIT 1 | 2,301 | 4,352 | 3,593 | 2,853 | 3,023 | 3,657 | 4,785 | 5,228 |
| Operating Margin | 2.31% | 3.93% | 2.93% | 2.03% | 2.01% | 2.15% | 2.51% | 2.32% |
| Earnings before Tax (EBT) 1 | 2,317 | 4,334 | 3,363 | 2,838 | 2,991 | 3,614 | 4,369 | 5,195 |
| Net income 1 | 1,727 | 3,075 | 2,448 | 2,085 | 2,174 | 2,550 | 3,180 | 3,642 |
| Net margin | 1.74% | 2.77% | 2% | 1.48% | 1.45% | 1.5% | 1.67% | 1.62% |
| EPS 2 | 0.4410 | 0.7430 | 0.6088 | 0.5129 | 0.5500 | 0.5800 | 0.7787 | 0.7200 |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | 0.2397 | 0.1438 | 0.2397 | 0.2500 | 0.2500 | 0.3492 | - |
| Announcement Date | 4/28/20 | 4/26/21 | 4/25/22 | 4/24/23 | 4/26/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | 35,776 | 40,472 | 41,151 | 44,581 | 51,439 | 38,161 | 45,793 |
| EBITDA 1 | - | - | - | - | - | - | - | - | - | 1,323 | 1,418 | 1,608 | 1,313 | 1,527 |
| EBIT 1 | - | - | - | - | - | - | - | 614.6 | 665.4 | 1,142 | 1,237 | 1,427 | 1,070 | 1,283 |
| Operating Margin | - | - | - | - | - | - | - | 1.72% | 1.64% | 2.77% | 2.77% | 2.77% | 2.8% | 2.8% |
| Earnings before Tax (EBT) 1 | - | - | - | - | - | - | - | 618.7 | 661.8 | 925.8 | 1,003 | 1,157 | 886.7 | 1,064 |
| Net income 1 | - | - | - | - | - | - | - | 350.4 | 537.7 | 704.8 | 763.6 | 881.1 | 675.1 | 810.1 |
| Net margin | - | - | - | - | - | - | - | 0.98% | 1.33% | 1.71% | 1.71% | 1.71% | 1.77% | 1.77% |
| EPS 2 | 0.0192 | 0.1103 | 0.2061 | 0.1150 | 0.0815 | 0.1390 | 0.2000 | - | 0.1400 | 0.2300 | 0.1900 | 0.2100 | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | 0.3706 | - | - | - | 0.3875 |
| Announcement Date | 4/25/22 | 4/25/22 | 8/22/22 | 10/24/22 | 4/24/23 | 4/24/23 | 8/28/23 | 4/26/24 | 4/27/24 | - | - | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 2,381 | 2,884 | 2,102 | - | - | 9,245 | 12,560 | - |
| Net Cash position 1 | - | - | - | 2,170 | 2,372 | - | - | - |
| Leverage (Debt/EBITDA) | 0.8391 x | 0.5876 x | 0.5021 x | - | - | 1.694 x | 2.042 x | - |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | 9.32% | 15.9% | 11.4% | 8.98% | 9.04% | 10% | 11.2% | 11.6% |
| ROA (Net income/ Total Assets) | 2.51% | 4.05% | 2.94% | 2.34% | - | 2.6% | 2.75% | - |
| Assets 1 | 68,924 | 75,984 | 83,379 | 89,104 | - | 98,096 | 115,639 | - |
| Book Value Per Share 2 | 4.790 | 4.960 | 5.370 | 5.750 | 6.140 | 5.910 | 7.110 | 6.230 |
| Cash Flow per Share 2 | 0.7100 | 0.8800 | 0.8800 | 1.020 | 1.210 | 0.9700 | 1.380 | -0.1000 |
| Capex 1 | 1,175 | 1,158 | 1,215 | 1,083 | 885 | 1,056 | 1,363 | - |
| Capex / Sales | 1.18% | 1.04% | 0.99% | 0.77% | 0.59% | 0.62% | 0.71% | - |
| Announcement Date | 4/28/20 | 4/26/21 | 4/25/22 | 4/24/23 | 4/26/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
8.17
CNY
Average target price
10.18
CNY
Spread / Average Target
+24.66%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +16.55% | 4.41B | |
| +17.88% | 70.09B | |
| -1.07% | 24.01B | |
| +8.01% | 8.32B | |
| -18.28% | 8.23B | |
| 0.00% | 8.08B | |
| +4.40% | 4.68B | |
| -0.70% | 4.12B | |
| -2.20% | 3.88B | |
| +26.24% | 3.71B |
- Stock Market
- Equities
- 600998 Stock
- Financials Jointown Pharmaceutical Group Co., Ltd